NR1I2 and chronic myelogenous leukemia, BCR-ABL1 positive: To our knowledge, there are no publications available on the effect of single-nucleotide polymorphisms in the PXR and CAR nuclear receptor genes on the outcomes of dasatinib treatment in CML patients.